$9.62 Million in Sales Expected for Immatics (NASDAQ:IMTX) This Quarter


Share on StockTwits

Equities analysts expect that Immatics (NASDAQ:IMTX) will report $9.62 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Immatics’ earnings, with estimates ranging from $8.26 million to $10.97 million. The firm is expected to report its next quarterly earnings results on Tuesday, June 29th.

On average, analysts expect that Immatics will report full year sales of $44.37 million for the current year, with estimates ranging from $37.64 million to $51.80 million. For the next fiscal year, analysts expect that the company will post sales of $40.08 million, with estimates ranging from $38.00 million to $43.78 million. Zacks’ sales averages are a mean average based on a survey of research firms that cover Immatics.

A number of equities research analysts have commented on the company. Zacks Investment Research lowered Immatics from a “hold” rating to a “sell” rating in a research report on Monday, March 22nd. SVB Leerink boosted their price objective on shares of Immatics from $17.00 to $26.00 and gave the company an “outperform” rating in a research report on Tuesday, March 23rd. Finally, Chardan Capital reiterated a “buy” rating on shares of Immatics in a research note on Sunday, April 4th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Immatics presently has a consensus rating of “Buy” and a consensus price target of $19.60.

Large investors have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. lifted its stake in Immatics by 26.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 2,171,889 shares of the company’s stock valued at $23,435,000 after acquiring an additional 457,265 shares during the last quarter. Squarepoint Ops LLC lifted its stake in shares of Immatics by 31.9% in the 4th quarter. Squarepoint Ops LLC now owns 27,618 shares of the company’s stock valued at $298,000 after purchasing an additional 6,680 shares during the last quarter. Baker BROS. Advisors LP boosted its holdings in Immatics by 80.2% in the fourth quarter. Baker BROS. Advisors LP now owns 1,805,025 shares of the company’s stock worth $19,476,000 after purchasing an additional 803,611 shares in the last quarter. Penserra Capital Management LLC boosted its holdings in Immatics by 688.8% in the fourth quarter. Penserra Capital Management LLC now owns 44,047 shares of the company’s stock worth $475,000 after purchasing an additional 38,463 shares in the last quarter. Finally, LPL Financial LLC increased its position in Immatics by 19.0% during the fourth quarter. LPL Financial LLC now owns 12,943 shares of the company’s stock worth $140,000 after buying an additional 2,070 shares during the last quarter.

Shares of IMTX stock traded down $0.46 on Thursday, reaching $11.99. 165,621 shares of the company’s stock traded hands, compared to its average volume of 641,543. Immatics has a 12-month low of $8.66 and a 12-month high of $18.42. The business’s 50 day moving average price is $12.32 and its two-hundred day moving average price is $11.08.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Featured Story: What does EPS mean?

Get a free copy of the Zacks research report on Immatics (IMTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immatics (NASDAQ:IMTX)

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.